Overall market sentiment has been down on Iovance Biotherapeutics Inc (IOVA) stock lately. IOVA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Iovance Biotherapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IOVA!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With IOVA Stock Today?
Iovance Biotherapeutics Inc (IOVA) stock is trading at $11.01 as of 3:38 PM on Friday, Aug 26, a drop of -$0.68, or -5.82% from the previous closing price of $11.69. The stock has traded between $10.94 and $11.73 so far today. Volume today is less active than usual. So far 1,372,017 shares have traded compared to average volume of 2,442,122 shares.
To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.
More About Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma.
Click Here to get the full Stock Report for Iovance Biotherapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
